BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Scott LJ. Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C. Drugs 2018;78:245-56. [DOI: 10.1007/s40265-018-0864-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Yang CHT, Goel A, Ahmed A. Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C. Adolesc Health Med Ther 2018;9:103-10. [PMID: 30104913 DOI: 10.2147/AHMT.S147896] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Llaneras J, Riveiro-Barciela M, Lens S, Diago M, Cachero A, García-Samaniego J, Conde I, Arencibia A, Arenas J, Gea F, Torras X, Luis Calleja J, Antonio Carrión J, Fernández I, María Morillas R, Rosales JM, Carmona I, Fernández-Rodríguez C, Hernández-Guerra M, Llerena S, Bernal V, Turnes J, González-Santiago JM, Montoliu S, Figueruela B, Badia E, Delgado M, Fernández-Bermejo M, Iñarrairaegui M, Pascasio JM, Esteban R, Mariño Z, Buti M. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. J Hepatol 2019;71:666-72. [PMID: 31203153 DOI: 10.1016/j.jhep.2019.06.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 10.3] [Reference Citation Analysis]
3 Liu J, Han J, Izawa K, Sato T, White S, Meanwell NA, Soloshonok VA. Cyclic tailor-made amino acids in the design of modern pharmaceuticals. Eur J Med Chem 2020;208:112736. [PMID: 32966895 DOI: 10.1016/j.ejmech.2020.112736] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
4 Pirzada RH, Haseeb M, Batool M, Kim M, Choi S. Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication. Cells 2021;10:1052. [PMID: 33946869 DOI: 10.3390/cells10051052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Sun HY, Cheng CY, Lin CY, Yang CJ, Lee NY, Liou BH, Tang HJ, Liu YM, Lee CY, Chen TC, Huang YC, Lee YT, Tsai MJ, Lu PL, Tsai HC, Wang NC, Hung TC, Cheng SH, Hung CC. Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections. World J Gastroenterol 2022; 28(11): 1172-1183 [DOI: 10.3748/wjg.v28.i11.1172] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Hanif FM, Majid Z, Luck NH, Tasneem AA, Laeeq SM, Mubarak M. Revolution in the diagnosis and management of hepatitis C virus infection in current era. World J Hepatol 2022; 14(4): 647-669 [DOI: 10.4254/wjh.v14.i4.647] [Reference Citation Analysis]
7 Zhang W, Lv Y, Yang J, Chen Y, He Y, Huang J. Study Design Characteristics and Pharmacological Mechanisms in International Clinical Trials Registry Platform: Registered Clinical Trials on Antiviral Drugs for COVID-19. Drug Des Devel Ther 2020;14:3803-13. [PMID: 32982184 DOI: 10.2147/DDDT.S272442] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Saab S, Kullar R, Gounder P. The Urgent Need for Hepatitis C Screening in Pregnant Women: A Call to Action. Obstetrics & Gynecology 2020;135:773-7. [DOI: 10.1097/aog.0000000000003704] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Corma-Gómez A, Macías J, Merino Muñoz D, Téllez F, Granados R, Morano LE, De Los Santos Gil I, Vera-Méndez FJ, Collado A, Palacios R, Pineda JA. Higher relapse rate among HIV/HCV-coinfected patients receiving sofosbuvir/ledipasvir for 8 vs 12 weeks. J Infect 2019;79:30-5. [PMID: 31100364 DOI: 10.1016/j.jinf.2019.05.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
10 Huffman V, Andrade DC, Sherman E, Niu J, Eckardt PA. Treatment of chronic hepatitis C virus infection with crushed ledipasvir/sofosbuvir administered through a percutaneous endoscopic gastrostomy tube in a patient with HIV coinfection. Am J Health Syst Pharm 2021;78:36-40. [PMID: 33037429 DOI: 10.1093/ajhp/zxaa328] [Reference Citation Analysis]
11 Razafindrazoto CI, Rasolonjatovo AS, Rabenjanahary TH, Randriamifidy NH, Rakotozafindrabe ALR, Razafimahefa SH, Ramanampamonjy RM. Treatment of viral hepatitis C genotypes 1 and 2 by sofosbuvir and ledipasvir with or without ribavirin combination: A possible alternative to pangenotypic treatment in a low-income country? Int J Infect Dis 2021;107:166-9. [PMID: 33895411 DOI: 10.1016/j.ijid.2021.04.061] [Reference Citation Analysis]
12 Yang X, Tang Y, Xu D, Zhang G, Xu P, Tang H, Pang L. Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis. Virol J 2021;18:156. [PMID: 34315488 DOI: 10.1186/s12985-021-01625-w] [Reference Citation Analysis]
13 Mei H, Han J, White S, Graham DJ, Izawa K, Sato T, Fustero S, Meanwell NA, Soloshonok VA. Tailor-Made Amino Acids and Fluorinated Motifs as Prominent Traits in Modern Pharmaceuticals. Chemistry 2020;26:11349-90. [PMID: 32359086 DOI: 10.1002/chem.202000617] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 16.5] [Reference Citation Analysis]